News

Cytori Receives Orphan Drug Designation in Europe for Scleroderma Cellular Therapy

The European Commission has granted late stage cell therapy company Cytori Therapeutics, Inc.’s ECCS-50 cellular therapy the designation of orphan medicinal product for the treatment of scleroderma. The decision, which was made due to positive references from the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products, represents the first time an…

Systemic Sclerosis-overlap Syndrome To Be Taken A New Disease Subset

Researchers from the University of Cologne in Germany showed that Systemic sclerosis-overlap Syndrome should be regarded as different separate subset in Systemic sclerosis (SSc) patients. The study entitled “Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis” appeared on…

Researchers Evaluate the Effect of Ambrisentan on Digital Blood Flow in Patients with Systemic Sclerosis using Laser Doppler Perfusion Imaging

Researchers from the Hunter Holmes McGuire VA Medical Center, Richmond, VA, and the Department of Rheumatic and Immunologic Diseases, Orthopedics and Rheumatology Institute, Cleveland Clinic, OH, have recently released results from a clinical trial that evaluated the use of ambrisentan, a selective endothelin type A receptor antagonist,…